<DOC>
	<DOCNO>NCT01592747</DOCNO>
	<brief_summary>This clinical study 12-week , multicenter , double-blind , placebo-controlled , randomize withdrawal study pediatric outpatient autism , Asperger 's Disorder , Pervasive Developmental Disorder Not Otherwise Specified ( PDD-NOS ) . The objective evaluate safety , tolerability , efficacy memantine therapy compare placebo .</brief_summary>
	<brief_title>Withdrawal Study Memantine Pediatric Patients With Autism , Asperger 's Disorder , Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine</brief_title>
	<detailed_description>This clinical study 12-week , multicenter , double-blind , placebo-controlled , randomize withdrawal study pediatric outpatient autism , Asperger 's Disorder , Pervasive Developmental Disorder Not Otherwise Specified ( PDD-NOS ) conduct approximately 180 study center . Patients complete least 12 week study drug exposure lead-in study MEM-MD-91 meet protocol specify responder criterion .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Developmental Disabilities</mesh_term>
	<mesh_term>Asperger Syndrome</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>1 . Completed least 12 week exposure study drug leadin study MEMMD91 2 . Met responder criterion two consecutive visit separate least two week leadin study MEMMD91 3 . Provide write informed assent , developmentally appropriate , participate study conduct studyspecific procedure . The parent/guardian/LAR must provide write informed consent patient 's participation study . A separate write informed consent caregiver must also obtain conduct study specific procedures 4 . Have knowledgeable caregiver capable provide reliable information patient 's condition , attend clinic visit patient , oversee administration study drug . Every effort make maintain caregiver use leadin study throughout study 5 . Have normal result physical examination , laboratory test , ECG , vital sign Visit 1 study ( last visit Study MEMMD91 ) . Any abnormal finding must deem clinically significant Investigator document 6 . Be able speak understand English sufficiently ( native language accommodate site ) , well caregiver parent/guardian/LAR able speak understand English sufficiently ( native language accommodate site ) , comprehend nature study allow completion study assessment 7 . Have family sufficiently organize stable guarantee adequate safety monitor continuous attendance clinic visit duration study 8 . Females 9 year old onset menses must negative urine pregnancy test Visit 1 1 . Patients concurrent medical condition might interfere conduct study , confound interpretation study result , endanger patient 's well 2 . Significant risk suicidality 3 . Patients evidence history malignancy ( excise basal cell carcinoma ) significant hematologic , endocrine , cardiovascular ( include rhythm disorder ) , neurologic , respiratory , renal , hepatic , gastrointestinal disease 4 . Female patient childbearing potential use willing use conventional method contraception approve PI . Abstinence acceptable method contraception 5 . Patients require treatment prohibit concomitant medication 6 . Patients , opinion Investigator , might suitable study 7 . Employee immediate relative employee Forest Laboratories , Inc. , affiliate partner , study center</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Asperger 's</keyword>
	<keyword>Pervasive Developmental Disorder Not Otherwise Specified ( PDD-NOS )</keyword>
	<keyword>Memantine</keyword>
	<keyword>Pervasive Child Development Disorder</keyword>
	<keyword>Pediatric Disorder</keyword>
	<keyword>Randomized Controlled Trial</keyword>
</DOC>